Xtant Medical Holdings, Inc. (XTNT)
| Market Cap | 72.84M +9.0% |
| Revenue (ttm) | 133.93M +14.2% |
| Net Income | 4.97M |
| EPS | 0.03 |
| Shares Out | 140.07M |
| PE Ratio | 17.33 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 285,382 |
| Open | 0.5501 |
| Previous Close | 0.5700 |
| Day's Range | 0.5200 - 0.5613 |
| 52-Week Range | 0.4380 - 0.9500 |
| Beta | -0.12 |
| Analysts | Strong Buy |
| Price Target | 1.00 (+92.31%) |
| Earnings Date | May 13, 2026 |
About XTNT
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFact... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for XTNT stock is "Strong Buy" and the 12-month stock price target is $1.0.
News
Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026
BELGRADE, Mont., May 7, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, ...
Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped
BELGRADE, Mont., May 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, ...
Xtant Medical resumed with a Buy at Maxim
Maxim resumed coverage of Xtant Medical (XTNT) with a Buy rating and $1.50 price target With the overall focus on the higher-growth and higher-margin orthobiologics business, Xtant is positioned for
Xtant Medical acquires U.S. distribution rights to Dilon’s Hemoblast Bellows
Xtant Medical (XTNT) Holdings and Dilon Technologies announced that the companies have entered into an agreement whereby Xtant has acquired exclusive U.S. distribution rights to Dilon’s Hemoblast Bell...
Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product
Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST ® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE, Mont...
Xtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial
BELGRADE, Mont., April 9, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), in partnership with the Montana Governor's Office of Community Service (GOCS), today announced suppor...
Xtant Medical Holdings Earnings Call Transcript: Q4 2025
Revenue grew 14% in 2025 to $133.9M, with strong gross margin and a return to profitability. 2026 guidance reflects divestitures and non-recurring revenue loss, but core biologics is expected to accelerate as new products and expanded sales force drive growth.
Xtant Medical sees 2026 revenue $95M-$99M, consensus $110.1M
07:04 EDT Xtant Medical (XTNT) sees 2026 revenue $95M-$99M, consensus $110.1M
Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December 3...
Xtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
BELGRADE, Mont., March 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic condition...
Xtant Medical Holdings Transcript: 2026 CG Musculoskeletal Conference
Strong growth and profitability were driven by vertical integration, product innovation, and strategic divestitures. Expanded product lines and new market entries, including OEM and wound care, support future growth, while a strengthened balance sheet and operational focus position the company for continued success.
Xtant Medical says transactions with Companion Spine now finalized
Xtant Medical (XTNT) Holdings announced that it has received $10.7M from Companion Spine related to Companion Spine’s purchase of Xtant’s Coflex assets and Paradigm OUS businesses in December 2025, br...
Xtant Medical Finalizes Companion Spine Transactions
Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments BELGRADE, Mont., March 2, 2026 /PRNewswire/ -- Xta...
Xtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference
BELGRADE, Mont., Feb. 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthop...
Xtant Medical announces commercial launch of Strata
Xtant Medical (XTNT) Holdings announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata. Strata is available in compression-resistant preformed ...
Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft
nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity BELGRADE, Mo...
Xtant Medical Completes Sale of its Coflex® Assets and Paradigm OUS Businesses to Companion Spine
BELGRADE, Mont. , Dec. 1, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic con...
Xtant Medical price target lowered to $1.50 from $2 at BTIG
BTIG lowered the firm’s price target on Xtant Medical (XTNT) to $1.50 from $2 and keeps a Buy rating on the shares. Xtant Medical reported Q3 revenue up 19% year
Xtant Medical Holdings Earnings Call Transcript: Q3 2025
Q3 2025 saw 19% revenue growth to $33.3M, improved gross margin, and a return to profitability, driven by licensing and biologics. Pending sale of non-core assets will enhance liquidity and focus, with 2025 revenue guidance reiterated at $131–$135M.
Xtant Medical still sees 2025 revenue $131M-$135M vs. $117.27M in 2024
16:31 EST Xtant Medical (XTNT) still sees 2025 revenue $131M-$135M vs. $117.27M in 2024
Xtant Medical Reports Third Quarter 2025 Financial Results
Total Revenue of $33.3 Million Increased 19% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Reiterates FY25 Revenue Guidance of $131-$135 Million, Representing Gr...
Xtant Medical Announces Commercial Launch of CollagenX™
Launch further expands Xtant's biologics product portfolio to include surgical wound closure BELGRADE, Mont. , Nov. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global...
Xtant Medical to Announce Third Quarter 2025 Financial Results on November 11, 2025
BELGRADE, Mont. , Nov. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthop...
Xtant Medical Holdings Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The presentation highlighted strong growth, improved profitability, and a sharpened focus on core orthobiologics through divestitures and vertical integration. New product launches and a robust pipeline support expansion into adjacent markets, with no need for additional capital.
Xtant Medical to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
BELGRADE, Mont. , Sept. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, ortho...